Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial | Zendy

Luís M. Ruilope | Zendy; Rajiv Agarwal | Zendy; Stefan D. Anker | Zendy; George L. Bakris | Zendy; Jingmei Li | Zendy; Christiowack | Zendy; Peter Kolkhof | Zendy; Amer Joseph | Zendy; Nicole Mentenich | Zendy; Bertram Pitt | Zendy

Open Access

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

Author(s) -

Luís M. Ruilope,

Rajiv Agarwal,

Stefan D. Anker,

George L. Bakris,

Jingmei Li,

Christiowack,

Peter Kolkhof,

Amer Joseph,

Nicole Mentenich,

Bertram Pitt

Publication year - 2019

Publication title -

american journal of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.394

H-Index - 85

eISSN - 1421-9670

pISSN - 0250-8095

DOI - 10.1159/000503712

Subject(s) - medicine , kidney disease , diabetes mellitus , disease , intensive care medicine , baseline (sea) , medline , randomized controlled trial , endocrinology , oceanography , political science , law , geology

Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research